Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/202a3453a4724bdbaf304549fd75661f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:202a3453a4724bdbaf304549fd75661f
record_format	dspace
spelling	oai:doaj.org-article:202a3453a4724bdbaf304549fd75661f2021-12-02T00:29:56ZReasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes1178-7007https://doaj.org/article/202a3453a4724bdbaf304549fd75661f2017-09-01T00:00:00Zhttps://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs.Materials and methods: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use.Results: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues “Made me feel sick” (64.4%) and “Made me throw up” (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were “Prefer oral medication over injections” (patients 56%, physicians 32.6%), “Made me feel sick” (patients 38.1%, physicians 16.3%), and “Did not help lose weight” (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were “Difficult to plan meals around” (55.6%), “Made me throw up” (51.6%), and “Caused weight gain” (50%).Conclusion: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician–patient communication. Understanding patients’ expectations of GLP1 RAs and physicians’ patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care. Keywords: antidiabetic drug, cross-sectional survey, discontinuation, incretins, incretin therapy, glycemic controlSikirica MVMartin AAWood RLeith APiercy JHiggins VDove Medical Pressarticleantidiabetic drugcross-sectional surveydiscontinuationincretinsincretin therapyglycemic controlSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 403-412 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control Specialties of internal medicine RC581-951
spellingShingle	antidiabetic drug cross-sectional survey discontinuation incretins incretin therapy glycemic control Specialties of internal medicine RC581-951 Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
description	Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs.Materials and methods: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use.Results: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues “Made me feel sick” (64.4%) and “Made me throw up” (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were “Prefer oral medication over injections” (patients 56%, physicians 32.6%), “Made me feel sick” (patients 38.1%, physicians 16.3%), and “Did not help lose weight” (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were “Difficult to plan meals around” (55.6%), “Made me throw up” (51.6%), and “Caused weight gain” (50%).Conclusion: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician–patient communication. Understanding patients’ expectations of GLP1 RAs and physicians’ patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care. Keywords: antidiabetic drug, cross-sectional survey, discontinuation, incretins, incretin therapy, glycemic control
format	article
author	Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V
author_facet	Sikirica MV Martin AA Wood R Leith A Piercy J Higgins V
author_sort	Sikirica MV
title	Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
title_short	Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
title_full	Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
title_fullStr	Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
title_full_unstemmed	Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
title_sort	reasons for discontinuation of glp1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/202a3453a4724bdbaf304549fd75661f
work_keys_str_mv	AT sikiricamv reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT martinaa reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT woodr reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT leitha reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT piercyj reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes AT higginsv reasonsfordiscontinuationofglp1receptoragonistsdatafromarealworldcrosssectionalsurveyofphysiciansandtheirpatientswithtype2diabetes
_version_	1718403662400716800

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Ejemplares similares